(Q26864063)

Daniel Ferreira

1

0 references

Eric Westman

Eric Westman

Lilisbeth Perestelo-Pérez

3

0 references

2

Lilisbeth Perestelo-Pérez

1 reference

Pedro Serrano-Aguilar

6

Pedro Serrano-Aguilar

1 reference

Antonio Sarría

5

1 reference

language of work or name

1 reference

2014

1 reference

Frontiers in Aging Neuroscience

published in

1 reference

volume

6

1 reference

page(s)

47

1 reference

Biological markers of amyloid beta-related mechanisms in Alzheimer's disease

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Forecasting the global burden of Alzheimer’s disease

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Global prevalence of dementia: a Delphi consensus study

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Alzheimer Disease in the US Population

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Neuropathological stageing of Alzheimer-related changes

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Mild cognitive impairment: clinical characterization and outcome

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Mild cognitive impairment as a diagnostic entity

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

BrainAGE in Mild Cognitive Impaired Patients: Predicting the Conversion to Alzheimer's Disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Prevalence of Alzheimer's pathologic endophenotypes in asymptomatic and mildly impaired first-degree relatives

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Biomarkers of Alzheimer disease: current and future applications to diagnostic criteria

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Predicting AD conversion: comparison between prodromal AD guidelines and computer assisted PredictAD tool

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

CSF and brain structural imaging markers of the Alzheimer's pathological cascade

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Enrichment and stratification for predementia Alzheimer disease clinical trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Cerebrospinal fluid biomarkers for Alzheimer's disease: more to come?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

The development of effective biomarkers for Alzheimer's disease: a review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

CSF biomarkers cutoffs: the importance of coincident neuropathological diseases

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Age and diagnostic performance of Alzheimer disease CSF biomarkers.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

CSF biomarkers for Alzheimer's disease: current utility and potential future use.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Predicting MCI outcome with clinically available MRI and CSF biomarkers

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Tau and p-tau as CSF biomarkers in dementia: a meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Biomarkers for early detection of Alzheimer disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Serial MRI and CSF biomarkers in normal aging, MCI, and AD

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Comparing predictors of conversion and decline in mild cognitive impairment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Current concepts in mild cognitive impairment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Characterization of beta-amyloid peptide from human cerebrospinal fluid

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Users' guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Preclinical AD predicts decline in memory and executive functions in subjective complaints

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

CSF Biomarkers for Alzheimer's Disease Diagnosis

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Multicenter clinicopathological correlation in dementia

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Clinically diagnosed Alzheimer disease: neuropathologic findings in 650 cases.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease.

31 May 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

A new decision tree combining Abeta 1-42 and p-Tau levels in Alzheimer's diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Relationship between atrophy and beta-amyloid deposition in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Retrospective evaluation of revised criteria for the diagnosis of Alzheimer's disease using a cohort with post-mortem diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

CSF metabolites in the differential diagnosis of Alzheimer's disease from frontal variant of frontotemporal dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Combination of hippocampal volume and cerebrospinal fluid biomarkers improves predictive value in mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Cerebrospinal fluid biomarkers in Alzheimer's disease families with PSEN1 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Age-dependent decline in the apolipoprotein E level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Supporting evidence for using biomarkers in the diagnosis of MCI due to AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

International quality control survey of neurochemical dementia diagnostics.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

The AD-CSF-index discriminates Alzheimer's disease patients from healthy controls: a validation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

A comparison of early diagnostic utility of Alzheimer disease biomarkers in brain magnetic resonance and cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Disease state fingerprint in frontotemporal degeneration with reference to Alzheimer's disease and mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Use of Alzheimer disease biomarkers: potentially yes for clinical trials but not yet for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Biochemical markers in persons with preclinical familial Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same?

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Phases of A beta-deposition in the human brain and its relevance for the development of AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

A Canadian Cohort Study of Cognitive Impairment and Related Dementias (ACCORD): Study Methods and Baseline Results

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease” 11The names of the Working Group Members and the names of the Working Group Advisory Committee Members are listed in the Appendix A(section VI)

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNAGI.2014.00047

[A new approach to the Alzheimer's disease diagnosis with biomarkers: description of the AD-CSF-Index].

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

[Biomarkers in the cerebrospinal fluid of patients with mild cognitive impairment: a meta-analysis of their predictive capacity for the diagnosis of Alzheimer's disease].

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970033

Detection of dementia in primary care: the Linköping study

28 November 2018

1 reference

12 December 2020

Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment

1 reference

12 December 2020

Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group

1 reference

12 December 2020

Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression

1 reference

12 December 2020

Relationships among cerebrospinal fluid biomarkers in dementia of the Alzheimer type

1 reference

12 December 2020

Development of an ultra-rapid diagnostic method based on heart-type fatty acid binding protein levels in the CSF of CJD patients

1 reference

12 December 2020

The pathological process underlying Alzheimer's disease in individuals under thirty

1 reference

12 December 2020